Valerio Therapeutics Société anonyme (C4X.F)
| Previous Close | 0.1120 |
| Open | 0.1040 |
| Bid | 0.1002 x 460000 |
| Ask | 0.1254 x 450000 |
| Day's Range | 0.1040 - 0.1120 |
| 52 Week Range | 0.0840 - 0.3320 |
| Volume | |
| Avg. Volume | 255 |
| Market Cap | 17.411M |
| Beta (5Y Monthly) | 1.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireValerio Therapeutics Announces a Capital Reduction Motivated by Losses by Reducing the Nominal Value of the Company's Shares
PARIS, February 06, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter "Valerio Therapeutics" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announces a reduction of the par value of its shares.
Business WireHalf-Year Liquidity Contract Statement for Valerio Therapeutics
PARIS, January 31, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO)
Business WireValerio Therapeutics Reports its Half-Year 2023 Financial Results and Provides an Update on its Activities
PARIS, September 28, 2023--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter "Valerio Therapeutics" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today reports its consolidated half-year financial results to June 30, 2023, and provides an update on its activities.
